June 30, 2020Open Access

Treatment of Chronic Migraine with Erenumab Alone or as an Add on Therapy: A Real-World Observational Study

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Objectives: Chronic migraineurs having failed more than 3 preventive drugs were treated with Erenumab alone or as an add on therapy, we assessed the frequency of monthly migraine days, the value of an add on therapy, and all adverse events.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Guy Boudreau (Tue,) studied this question.

synapsesocial.com/papers/6a0067e464548b97a42d842e https://doi.org/https://doi.org/10.33425/2639-846x.1037

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches2015 · 72 citations
2Blocking CGRP in migraine patients – a review of pros and cons2017 · 302 citations
3CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications2019 · 196 citations
4Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study2018 · 157 citations
5Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial2017 · 735 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo